Impact of direct oral anticoagulant off-label doses on clinical outcomes of atrial fibrillation patients: A systematic review.

Joana SantosNatália AntónioMarília RochaAna Fortuna

Published in: British journal of clinical pharmacology (2020)

Patients prescribed with off-label DOAC doses did not receive the full benefit of anticoagulation and presented an increased risk of stroke, bleeding and/or adverse effects.

Keyphrases

atrial fibrillation
end stage renal disease
newly diagnosed
ejection fraction
chronic kidney disease
prognostic factors
direct oral anticoagulants
left atrial
oral anticoagulants
patient reported outcomes